AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Core Insights - AIM ImmunoTech Inc. has appointed David Chemerow as an Independent Director to its Board of Directors, effective immediately [1] - Mr. Chemerow has over 40 years of experience in finance, accounting, and operations across various industries, including significant roles at Comscore, Inc. and Rentrak Corporation [2] - The Chairman of AIM's Board, William Mitchell, expressed confidence in Mr. Chemerow's leadership and financial acumen, which are expected to contribute to AIM's mission [6] Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for treating cancers, immune disorders, and viral diseases, including COVID-19 [7] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials for significant health issues [7]